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INTRODUCTION 
Control of airway is one of the defining moments of Anaesthesia. 
Before the twentieth century, intubation of the trachea had been 
described and performed rather crudely, often using fingers as a makeshift 
laryngoscope without using  any pharmacological agents. At that time the only 
regular intubation of the trachea that was taking place was in the resuscitation 
of asphyxiated neonate. 
In 1880, Sir William Maceven,(1) a Scottish surgeon was the first to 
perform endotracheal intubation.  
In 1895 Kirstein became the first to perform endotracheal intubation 
using a laryngoscope. 
The credit of developing the scientific principles of direct laryngoscopy 
and endotracheal intubation belongs to the American otolaryngologist Dr. 
Chevallier Jackson. 
In 1913-jackson devised a U-shaped laryngoscope.  
In 1913-Janeway introduced L-shaped laryngoscope with batteries in the 
handle.  
Now we use rigid direct laryngoscopes to view the larynx and adjacent 
structures under direct vision for the purpose of endotracheal intubation. This 
causes direct trauma to the oropharynx and larynx and apart from this it also 
causes stimulation resulting in rise in heart rate, systolic blood pressure, 
diastolic blood pressure and mean arterial pressure. 
Tachycardia, hypertension and dysrythymias all occur during 
laryngoscopy and intubations. The consequent rise in rate/pressure product may 
result in a myocardial oxygen demand which exceeds the oxygen supply 
resulting in myocardial ischeamia2.This response is sympathetically mediated 
and can be attenuated by various drugs that block sympathetic activity and 
other drugs like calcium channel blocking drugs, lignocaine and magnesium. 
Studies have documented myocardial ischeamic changes due to reflex 
sympatho adrenal response immediately following laryngoscopy and intubation 
with a mean increase in systemic pressure of 40mmHg even in normotensive 
patients. 
An increase in heart rate is more likely to produce signs of myocardial 
ischeamia than hypertension on the ECG. Indeed, in anaesthetized patient, the 
incidence of myocardial ischeamia on the ECG sharply increases in patients 
who experience a heart rate greater than 110bpm (ischeamic threshold). A 
frequent recommendation is to maintain heart rate and blood pressure within 
20% of normal awake value for that patient. 
Many attempts have been made to attenuate the pressor response to 
laryngoscopy and intubation. 
For eg. 
 Deep plane of anesthesia 
 Topical anesthesia 
 Use of ganglionic blockers 
 Use of intravenous local anaesthetics 
 Sodium nitroprusside infusion 
 Magnesium sulphate 
 Fentanyl 
 Use of sympathetic blockers(beta-blockers,alpha2agonists) 
 Calcium channel blockers. 
It has been clearly proven by various studies that sympathetic 
overactivity occurs during laryngoscopy and the importance of suppressing the 
sympathetic overactivity is well emphasized.  
  It has become evident that, 2adrenoceptor agonists may also be a 
useful class of drugs in conjunction with anesthesia (3). They simultaneously 
potentiate the effects of general anesthetic agents, reduce their dose 
requirements and attenuate sympathoadrenal responses to noxious stimuli 
encountered during anesthesia and surgery, thus providing improved 
haemodynamic, metabolic and hormonal stability (4). 
Dexmedetomidine is a highly selective and potent 2adrenoceptor 
agonist. It is a pure2adrenoceptor agonist (α1:α2 ratio-1:1600) than clonidine 
which has  only less selective agonist activity. (α1:α2 ratio-1:200) 
Labetolol is combined α1andβ antagonist. In patients with no history of 
hypertension or significant cardiac disease, labetalol 0.3 or 0.6mg/kg i.v. is 
suited to blunting tachycardia and hypertension to laryngoscopy and 
intubation5 
In this study which was carried out in the Institute of  Anaesthesiology 
and Critical care at Madras medical college hospital, we compared intravenous 
labetalol and dexmeditomidine in attenuating haemodynamic stress response 
(increase in heart rate and an increase in the mean arterial pressure) to 
laryngoscopy and intubation, and find out which drug is better. 
  
AIM 
This study was done with the following intentions: 
 To compare the efficacy of dexmeditomidine 1µg/kg; and 
labetolol 0.5mg/kg in attenuating the cardiovascular responses to 
Laryngoscopy and Intubation. 
 To observe any adverse effects of these two in the specified 
dosage. 
REVIEW OF LITERATURE 
Laryngoscopy and intubation were being performed over many years, 
and the hemodynamic consequences are studied by many authors by using 
many methods and drugs. 
Tachycardia and hypertension commonly occur during anaesthesia due 
to manyfactors like mechanical stimulation, and complex interaction of  
hypoxia, hypercapnia and circulating levels of catecholamines. 
KING et.al7.in 1951.showed that there was a marked rise in blood 
pressure and heart rate during laryngoscopy which was due to the mechanical 
stimulation  of sensitive receptors in the area of epiglottis. 
KING and his associates7 (1960) believed the reflex mechanisms to be 
essentially non-specific in character. They stated that the impulses initiating the 
reflex arc are probably carried over the vagus, while the effector system is less 
clearly defined and may be due to decreased parasympathetic or increased 
sympathetic adrenal activity. 
KING et al (1951) used deep Ether anaesthesia to abolish the reflex 
circulatory response to tracheal intubation. 
WYCOFF C.C.33(1960) in his study stated that topical anaesthesia of 
the pharynx along with superior laryngeal nerve blocks, reduced the increase in 
mean arterial pressure after intubation. 
FORBES and DALLY (1970)5 observed that laryngoscopy and endo 
tracheal intubation is immediately associated with an average increase in mean 
arterial pressure of 25mm of Hg in all 22 normotensive patients. These 
responses were interpreted as due to reflex sympathetic adrenal stimulation. 
PRY ROBERT et al 6(1971) found that the increases in heart rate and 
blood pressure are much more exaggerated in hypertensive patients. 
FOEX et al (1971) observed 
i. Inotropic Failure 
ii. Ischemic arrhythmias and 
iii. Cerebrovascular accidents. 
In patients with uncontrolled hypertension who came up for emergency 
surgery and associated substantial increase in heart rate and blood pressure 
following laryngoscopy and endotracheal intubation which lasted for several 
minutes. 
CHUNG et.al.1in their study on haemodynamic responses to 
laryngoscopy and intubation showed maximum value of systolic, diastolic, 
mean arterial pressure and heart rate occur within 30 to 60 seconds of 
laryngoscopy and intubation, and in patients with hypertension, laryngoscopy 
and intubation led to left ventricular failure due to exaggerated pressure 
response. Similarly in patients with IHD transient myocardial ischaemia has 
been observed. 
ARIES & SIMONIES8 have correlated the levels of adrenaline and nor 
adrenaline with sympathetic innervation”. 
ROBERTS, C. GREEN, et. Al6showed an exaggerated form of rise in 
heart rate and mean arterial pressure in hypertensive patients during 
laryngoscopy and intubation. 
A.J. SHRIBIRAN, G. SMITH et. al9 in a study of haemodynamic 
stress response to laryngoscopy alone and laryngoscopy followed by 
intubation, was done in 24 patients and the heart rate, MAP, and the plasma 
catecholamines before laryngoscopy and at 1st,3rd, and 5th min after 
laryngoscopy was assessed. There was a significant increase in the heart rate, 
mean arterial pressure and plasma catecholamine concentration following 
laryngoscopy with or without intubation. 
ELLIOFF et al (1980) by echo cardiographic study found that there 
was substantial worsening of left ventricular wall function – akinesia, 
dyskinesia or hypokinesia following laryngoscopy and endotracheal intubation. 
STEVEN M. HELFMAN, et al10 observed that esmolol provides 
consistent and reliable protection from increase in both heart rate and systolic 
bloodpressure during and after intubation. Where as lignocaine and fentanyl 
failed to protect against increases in heart rate but provided protection against 
increase in systolic blood pressure equivalent to that provided by esmolol. 
FLACKE at al11(1987)observed that pre treatment with clonidine 
resulted in lower heart rate and blood pressure values both before and after 
induction as well as following endotracheal intubation and skin incision. 
SCHEININ B12et al: found that  Dexmedetomidine attenuated 
sympathoadrenal responses to tracheal intubation and reduced the need for 
thiopentone and peroperative fentanyl.   
GÜLERet al13.found that the increase in blood pressure and heart rate 
during the extubation is decreased and the quality of extubation is increased by 
dexmedetomidine. 
JAAKOLA et al.14found that , during the intubation blood pressure and 
heart rate is significantly reduced by 0.6 μg.kg-1dexmedetomidine. 
TEZER et al.15 found that sympathetic responses during laryngoscopy 
and intubation were effectively reduced by dexmedetomidine 1 μg.kg-1h-1 and 
esmolol 250 μg.kg-1min-1. 
KHAN et al.16 demonstrated that heart rate, systolic and diastolic blood 
pressure rise  after intubation were reduced by dexmedetomidine. 
AHO MS17 demonstrated the analgesic properties of dexmedetomidine 
using it as single agent after minor surgery. 
BERNSTEIN JSet al18:  demonstrated the attenuation of hemodynamic 
responses to rapid sequence induction and intubation with labetalol. 
INADA et al19. studied the effect of labetalol on the hemodynamic 
response to intubation. 
LESLIE JB et al.20  found that  pre induction intravenous labetalol  
attenuated the hemodynamic response to endotracheal intubation. 
CHUNG KS.et al21 studied The effect of an intermediate dose of 
labetalol on heart rate and blood pressure response to laryngoscopy and 
intubation. 
ANATOMY OF LARYNX 
 
NERVE SUPPLY OF LARYNX 
 
ANATOMY AND NERVE SUPPLY OF THE UPPER 
AIRWAY22 
The pharynx is a U shaped fibromuscular structure that extends from the 
base of the skull to the cricoid cartilage. It opens anteriorly into the nasal 
cavity, mouth and the larynx, which conveniently divides the pharynx into 
three parts termed as nasopharynx, oropharynx and laryngopharynx 
respectively. At the base of the tongue, the epiglottis functionally separate the 
oropharynx from the laryngopharynx. 
Sensory nerve supply of the upper airway is derived from the cranial 
nerves trigeminal, glossopharyngeal and the vagus. The palatine nerve provides 
sensory fibers from trigeminal nerve to hard and soft palate. The lingual nerve 
provides general sensation to the anterior two thirds of the tongue, and the 
glossopharyngeal nerve to the posterior one third of the tongue. 
Branches of the facial nerve and the glossopharyngeal nerve provide 
sensation of taste to anterior two thirds and posterior one third respectively. 
The glossopharyngeal nerve also innervates the roof of the pharynx, the 
tonsils and the undersurface of the soft palate. The pharyngeal surface of 
epiglottis is supplied by the glossopharyngeal nerve and the laryngeal surface 
of the epiglottis is supplied by the vagus nerve. Internal laryngeal branch of 
superior laryngeal branch provides sensory supply to the supra glottic area. The 
recurrent laryngeal nerve ascends to the larynx in the groove between the 
esophagus and trachea and divides into motor and sensory branches. 
The motor branch supplies all the intrinsic muscles of the larynx except 
cricothyroid. 
The sensory branch supplies the laryngeal mucous membrane below the 
level of vocal cords. 
PHYSIOLOGY OF STRESS RESPONSE23 
Haemodynamic stress response to laryngoscopy and intubation occurs as 
increase in the heart rate and the mean arterial pressure due to reflex 
sympathetic discharge in response to laryngo - tracheal stimulation. 
Tracheal intubation alters respiratory and cardiovascular physiology by 
reflex response and also by the physical presence of endotracheal tube. 
Although these circulatory responses are transient and of little consequence in 
patients with normal circulatory system, they may be exaggerated in patients 
with coronary artery disease, reactive airways and intracranial pathology. 
CARDIOVASCULAR RESPONSE 
This transitory variable and unpredictable response is mediated by both 
sympathetic and parasympathetic nervous systems. Usually bradycardia seen in 
neonates and infants during laryngoscopy and intubation is the autonomic 
equivalent of laryngospasm response in adults. This reflex is mediated by an 
increase in vagal tone at the SA node and is virtually a monosynaptic response 
to a noxious stimuli in the airway. 
The more common response to tracheal intubation is hypertension and 
tachycardia mediated by sympathetic efferents via the cardioaccelarator nerves 
and sympathetic chain ganglia .The polysynaptic nature of pathways from the 
IX and X nerve afferents to the sympathetic nervous system via the brain stem 
and spinal cord results in a diffuse autonomic response which includes 
widespread release of norepinephrine from the adrenergic terminals and release 
of epinephrine from the adrenal medulla. 
One other reason for the hypertensive response is due to activation of 
rennin- angiotensin system with release of renin from the renal juxtaglomerular 
apparatus, an end organ innervated by adrenergic nerve terminals. 
PHARMACOLOGY OF DEXMEDITOMIDINE24 
Dexmedetomidine is the most recently released IV anesthetic. It is a 
highly selective α2-adrenergic agonist that produces sedation, hypnosis, and 
analgesia. Dexmedetomidine is presently approved only for brief (<24 hours) 
postoperative sedation, although it is finding increasing use in the perioperative 
period as an adjunct sedative. Its primary action is as an agonist on α2 receptors 
in the locus caeruleus. It has minimal effect on respiration. Dexmedetomidine 
produces a biphasic effect on blood pressure; at low concentrations, mean 
blood pressure is decreased, and at higher concentrations, blood pressure is 
increased. Heart rate and cardiac output show a concentration-dependent 
decrease. Dosing for sedation is a loading dose of 0.25 to 1 mg/kg over a 10-
minute period, followed by an infusion of 0.1 to 1 µg/kg/hr. 
Physicochemical characteristics 
Dexmedetomidine is the d-enantiomer of medetomidine, a substance 
that has been used for sedation and analgesia in veterinary medicine for many 
years. It shows a high ratio of specificity for the α2 receptor α2/α1 (1600:1) 
compared with clonidine (α2/α1 200:1), making it a complete 2α agonist. 
 
Chemical structure of dexmedetomidine 
Metabolism and Pharmacokinetics25 
Dexmedetomidine belongs to the imidazole subclass of α2 receptor 
agonists.  
Dexmedetomidine is rapidly distributed and extensively metabolized in 
the liver and excreted in urine and feces. It undergoes conjugation (41%), n-
methylation (21%), or hydroxylation followed by conjugation.  
Dexmedetomidine is 94% protein bound, and its concentration ratio 
between whole blood and plasma is 0.66. 
Dexmedetomidine has profound effects on cardiovascular variables and 
may alter its own pharmacokinetics. With large doses, there is marked 
vasoconstriction, which probably reduces the drug's volumes of distribution. 
Elimination Half-Life (hr) Clearance (mL/kg/min) VdSS (L/kg) 
2-3 10-30 2-3 
 
 These pharmacokinetic parameters apparently are unaltered by age or 
weight or renal failure, but clearance is a function of height. The elimination 
half-life of dexmedetomidine is 2 to 3 hours, with a context-sensitive half-time 
ranging from 4 minutes after a 10-minute infusion to 250 minutes after an 8-
hour infusion. Postoperative patients sedated with dexmedetomidine display 
similar pharmacokinetics to the pharmacokinetics seen in volunteers26 
CLINICAL EFFECTS 
Effects on the Central Nervous System 
Sedation 
The α2 agonists produce their sedative-hypnotic effect by an action on α2 
receptors in the locus caeruleus and an analgesic action at α2 receptors within 
the locus caeruleus and within the spinal cord.27 The quality of sedation 
produced by dexmedetomidine seems different compared with that produced 
by other sedatives acting through the GABA systems. Patients receiving 
dexmedetomidine infusions as part of their sedation regimen in the 
postoperative ICU setting have been described as being very easy to wake up 
and having the ability to follow commands and cooperate while being 
tracheally intubated. Undisturbed, patients were noted to fall asleep.  
Despite sound levels of sedation with dexmedetomidine, there is limited 
respiratory depression, providing wide safety margins. This characteristic 
allows for “daily wake up” tests to be done in a safe fashion. This critical test—
when ventilated ICU patients are taken off all sedatives to assess their mental 
status and titrate sedation—shortens their ventilated and ICU length of stay. 
Mechanism of action 
The α2 agonists act through the endogenous sleep-promoting pathways 
to exert their sedative effect. Dexmedetomidine produces a decrease in activity 
of the projections of the locus caeruleus to the ventrolateralpreoptic nucleus. 
This increases GABAergic and galanin release in the tuberomammillary 
nucleus, producing a decrease in histamine release in cortical and subcortical 
projections. 
The α2 agonists seem to inhibit ion conductance through L-type or P-
type calcium channels and facilitate conductance through voltage-gated 
calcium-activated potassium channels. The similarity between natural sleep 
(non–rapid eye movement) and dexmedetomidine-induced hypnosis has been 
speculated to maintain cognitive and immunologic function in the sleep-
deprived states (as in the ICU) 
Dexmedetomidine can produce profound sedation, and it has been used 
as a total IV anesthetic when given at 10 times the normal sedation 
concentration range. 
Analgesia 
The analgesic effects of dexmedetomidine are complex. Alpha2 agonists 
do have an analgesic effect when injected via the intrathecal or epidural route. 
Clonidine injected in the neural axis helps with short-term pain, cancer pain, 
and neuropathic pain.  When dexmedetomidine is injected into the epidural 
space, it rapidly diffuses into the CSF. The effects on blood pressure are slower 
in onset with an epidural injection than with an intrathecal administration. 
Epidural effects are seen in 5 to 20 minutes. 
The primary site of analgesic action is thought to be the spinal cord. 
Systemic use of dexmedetomidine shows narcotic sparing. In the postoperative 
ICU setting, narcotic requirements were reduced by 50% when patients were 
receiving a dexmedetomidine drip compared with placebo. 
Other Central Nervous System Effects 
Administration of dexmedetomidine produced the predicted reduction of 
cerebral blood flow with a concomitant reduction in cerebral metabolic rate. 
This finding suggests the maintenance of the cerebral oxygen supply-to-
demand relationship. 
Dexmedetomidine has been used in neurosurgical procedures involving 
neurophysiologic monitoring. Cortical evoked potentials amplitudes and 
latencies were minimally affected when using dexmedetomidine 
intraoperatively when patients underwent craniotomies. Dexmedetomidine also 
is able to reduce muscle rigidity after high-dose opioid administration. 
Effects on the Respiratory System 
In volunteers, dexmedetomidine at concentrations producing significant 
sedation reduces minute ventilation, but retains the slope of the ventilatory 
response to increasing carbon dioxide. The changes in ventilation appeared 
similar to those observed during natural sleep. Infusing dexmedetomidine to 
concentrations of 15 ng/mL in spontaneously breathing volunteers, showed no 
change in arterial oxygenation or pH. At the highest concentrations, PaCO2 
increased by 20%. Respiratory rate increase with increasing concentration from 
14 breaths/min to 25 breaths/min. When dexmedetomidine and propofol were 
titrated to equal sedative end points (BIS of 85), both resulted in no change in 
respiratory rate. In a study comparing the effects of remifentanil and 
dexmedetomidine on respiratory parameters in normal volunteers the 
hypercapnic ventilatory response was unaffected even at doses that produced 
unresponsiveness to vigorous stimulation. PaCO2 increased mildly with 
dexmedetomidine, but it reached a plateau after the first increment. 
Dexmedetomidine also exhibited a hypercarbic arousal phenomenon, which 
has been described during normal sleep and is a safety feature. 
Effects on the Cardiovascular System 
The basic effects of α2 agonists on the cardiovascular system are 
decreased heart rate; decreased systemic vascular resistance; and indirectly 
decreased myocardial contractility, cardiac output, and systemic blood 
pressure. The hemodynamic effects of a bolus of dexmedetomidine in humans 
have shown a biphasic response. An acute IV injection of 2 µg/kg resulted in 
an initial increase in blood pressure (22%) and decrease in heart rate (27%) 
from baseline that occurred at 5 minutes after injection. This initial increase in 
blood pressure is probably due to the vasoconstrictive effects of 
dexmedetomidine when stimulating peripheral α2 receptors. Heart rate returned 
to baseline by 15 minutes, and blood pressure gradually declined to 
approximately 15% below baseline by 1 hour. After an IM injection of the 
same dose, the initial increase in blood pressure was not seen, and heart rate 
and blood pressure remained within 10% of baseline. 
The incidence of hypotension and bradycardia may be related to the 
administration  of a loading dose. Omitting the loading dose or not giving more 
than 0.4 µg/kg reduces the incidence of hypotension, or makes it less 
pronounced. Giving the loading dose over 20minutes also minimizes the 
transient hypertension. In several studies after IM and IV administration, 
dexmedetomidine caused, in a small percentage of patients, profound 
bradycardia (<40 beats/min) and occasionally sinus arrest/pause. Generally, 
these episodes resolved spontaneously or were readily treated without adverse 
outcome by anticholinergics. It would be expected from its profile that 
dexmedetomidine would be beneficial to the ischemic myocardium 
The perioperative use of α2 agonists reduces the incidence of 
perioperative myocardial ischemia. 
No rebound effects have been found when discontinuing 
dexmedetomidine drips, even when it is given for more than 24 hours 
A frequently reported side effect of dexmedetomidine has been a dry 
mouth. Dry mouth is due to a decrease in saliva production 
Uses  
Dexmedetomidine has been approved as a short-term sedative for adult 
intubated patients in the ICU. Given its well-documented beneficial effects of 
anxiolysis, sedation, analgesia, and sympatholysis with minimal respiratory 
depression, 
The unique characteristics of dexmedetomidine—providing adequate 
sedation with minimal respiratory depression—can be used when weaning 
patients from the ventilator. The use of dexmedetomidine to facilitate daily 
“wake up” tests in mechanically ventilated patients seems attractive 
As a premedicant, dexmedetomidine, at IV doses of 0.33 to 0.67 µg/kg 
given 15minutes before surgery, seems efficacious, while minimizing the 
cardiovascular side effects of hypotension and bradycardia. Within this dosage 
range, dexmedetomidine reduces thiopental requirements (by ±30%) for short 
procedures, reduces the requirements of volatile anesthetics (by ±25%), and 
more effectively attenuates the hemodynamic response to endotracheal 
intubation compared with 2 µg/kg of fentanyl. 
Dexmedetomidine also has been evaluated as an IM injection 
(2.5 µg/kg) with or without fentanyl administered 45 to 90 minutes before 
surgery. This regimen was compared with IM midazolam plus fentanyl and was 
found to provide equal anxiolysis, reduced response to intubation, smaller 
volatile anesthetic requirements, and a decreased incidence of postoperative 
shivering but a higher incidence of bradycardia. Atipamezole, a selective α2 
antagonist, at 50 µg/kg was effective in reversing the sedation of 
dexmedetomidine (2 µg/kg intramuscularly), when used to provide sedation for 
brief operative procedures. This reversal of effects resulted in a more rapid 
recovery than occurred after equisedative doses of midazolam. 
Dexmedetomidine has been used for sedation for monitored anesthesia 
care.28 
Dexmedetomidine sedation has been done successfully in pediatric 
patients.29 
When dexmedetomidine is used as a premedication 10 minutes before 
general surgery for cataract removal, intraocular pressure is decreased (33%), 
catecholamine secretion is reduced, perioperative analgesic requirements are 
less, and recovery is more rapid. 
For maintenance of anesthesia, dexmedetomidine has been used in 
patients undergoing multiple types of surgery. In patients given an infusion 
regimen to achieve a plasma concentration of slightly less than 1 ng/mL, 
combined with 70% nitrous oxide, dexmedetomidine reduced isoflurane 
requirements by 90% compared with a control group. 
Grant and colleagues described the use of dexmedetomidine when 
securing the airway with a fiberoptic intubation in three patients undergoing 
cervical spine surgery. The procedure was well tolerated with no hemodynamic 
compromise or respiratory depression.30 
Because this drug provides good sedation with minimal respiratory 
depression, it has been used in patients undergoing awake craniotomies with 
functional testing and electrocorticography or awake carotid endarterectomies 
with fewer fluctuations from the desired sedation level and more stable 
hemodynamics. 
Another use of dexmedetomidine has been as an anesthetic adjunct or 
sedative agent for patients who are susceptible to narcotic-induced respiratory 
depression or sleep apnea. In a morbidly obese patient, the narcotic-sparing 
effects of dexmedetomidine were evident intraoperatively and postoperatively 
after bariatric surgery. The addition of dexmedetomidine infusions to assist on 
transesophageal echocardiography examination has been described, with better 
hemodynamic profile and improved patient satisfaction than with 
benzodiazepine and narcotics alone, with no added respiratory depression. 
 This highly selective α2 agonist has a set of unique effects that include 
titratable sedation, sympatholysis, and analgesia without significant respiratory 
depression. Originally approved as a sedative in the ICU, it has found many 
off-label applications in the ICU, the operating room, and perioperative 
environment. The off-label use of dexmedetomidine in infants and children is 
rapidly increasing. 
PHARMACOLOGY OF LABETALOL31 
Labetalol Hydrochloride is an adrenergic receptor blocking agent that 
has both selective alpha-adrenergic and nonselective beta-adrenergic receptor 
blocking actions in a single substance. 
Labetalol hydrochloride (hcl) is a racemate consists of four isomers 
chemically designated as 5-[1-Hydroxy-2-[(1-methyl-3phenylpropyl) amino] 
ethyl] - salicylamidemonohydrochloride and it has the following structural 
formula:  
Chemical structure of labetalol 
 
Physical properties 
Labetalol has the molecular formula CHNO•hcland a molecular weight 
of 364.87.  
It has two asymmetric centers and therefore exists as a molecular 
complex of two diastereoisomeric pairs. Dilevalol, the R,R' stereoisomer, 
makes up 25% of racemic labetalol. 
Pharmacology32 
Labetalol combines both selective, competitive, alpha-adrenergic 
blocking and nonselective, competitive, beta-adrenergic blocking activity in a 
single substance. In man, the ratios of alpha- to beta-blockade have been 
estimated to be approximately 1:3 and 1:7 following oral and intravenous 
administration, respectively.  
The capacity of labetalol to block alpha receptors has been demonstrated 
by attenuation of the pressor effect of phenylephrine and by a significant 
reduction of the pressor response caused by immersing the hand in ice-cold 
water (“cold-pressor test”).  
Labetalol’s beta-receptor blockade was demonstrated by a small 
decrease in the resting heart rate, attenuation of tachycardia produced by 
isoproterenol or exercise, and by attenuation of the reflex tachycardia to the 
hypotension produced by amyl nitrite. Beta-receptor blockade was 
demonstrated by inhibition of the isoproterenol-induced fall in diastolic blood 
pressure. Both the alpha- and beta-blocking actions of orally administered 
labetalol contribute to a decrease in blood pressure in hypertensive patients. 
Labetalol consistently, in dose-related fashion, blunted increases in exercise-
induced blood pressure and heart rate, and in their double product. The 
pulmonary circulation during exercise was not affected by labetalol dosing. 
Single oral doses of labetalol administered to patients with coronary 
artery disease had no significant effect on sinus rate, intraventricular 
conduction, or QRS duration. The atrioventricular (A-V) conduction time was 
modestly prolonged. Intravenous labetalol slightly prolonged A-V nodal 
conduction time and atrial effective refractory period with only small changes 
in heart rate. The effects on A-V nodal refractoriness were inconsistent. 
Labetalol produces dose-related falls in blood pressure without reflex 
tachycardia and without significant reduction in heart rate, presumably through 
a mixture of its alpha-blocking and beta-blocking effects. Hemodynamic 
effects are variable, with small, nonsignificant changes in cardiac output seen 
in some studies but not others, and small decreases in total peripheral 
resistance. Elevated plasma renins are reduced. 
Metabolism  
The metabolism of labetalol is mainly through conjugation to 
glucuronide metabolites. These metabolites are present in plasma and are 
excreted in the urine and, via the bile, into the feces. Approximately 55% to 
60% of a dose appears in the urine as conjugates or unchanged labetalol within 
the first 24 hours of dosing. 
Labetalol has been shown to cross the placental barrier in humans. Only 
negligible amounts of the drug crossed the blood-brain barrier in animal 
studies. Labetalol is approximately 50% protein bound. Neither hemodialysis 
nor peritoneal dialysis removes a significant amount of labetalol from the 
general circulation (<1%). 
Following intravenous infusion of labetalol, the elimination half-life is 
about 5.5 hours and the total body clearance is approximately 33 ml/min/kg. 
The plasma half-life of labetalol following oral administration is about 6 to 8 
hours. In patients with decreased hepatic or renal function, the elimination half-
life of labetalol is not altered; however, the relative bioavailability in 
hepatically impaired patients is increased due to decreased “first-pass” 
metabolism 
Uses 
Labetalol hclinjection is indicated for control of blood pressure in severe 
hypertension. 
Intravenous labetalol has been shown to be effective in lowering blood 
pressure and relieving symptoms in patients with pheochromocytoma; higher 
than usual doses may be required. However, paradoxical hypertensive 
responses have been reported in a few patients with this tumor; therefore, use 
caution when administering labetalol to patients with pheochromocytoma. 
Labetalol is one of the drugs of choice in PIH as this drug does not 
reduce the uterine perfusion pressure. 
Drug interactions 
Since labetalol may be administered to patients already being treated 
with other medications, including other antihypertensive agents, careful 
monitoring of these patients is necessary to detect and treat promptly any 
undesired effect from concomitant administration 
Drug possessing beta-blocking properties can blunt the bronchodilator 
effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, 
doses greater than the normal antiasthmatic dose of beta-agonist bronchodilator 
drugs may be required. 
Cimetidine has been shown to increase the bioavailability of labetalol 
administered orally. Since this could be explained either by enhanced 
absorption or by an alteration of hepatic metabolism of labetalol, special care 
should be used in establishing the dose required for blood pressure control in 
such patients. 
Synergism has been shown between halothane anesthesia and 
intravenously administered labetalol. During controlled hypotensive anesthesia 
using labetalol in association with halothane, high concentrations (3% or 
above) of halothane should not be used because the degree of hypotension will 
be increased and because of the possibility of a large reduction in cardiac 
output and an increase in central venous pressure. The anesthesiologist should 
be informed when a patient is receiving labetalol. 
Labetalol blunts the reflex tachycardia produced by nitroglycerin 
without preventing its hypotensive effect. If labetalol is used with nitroglycerin 
in patients with angina pectoris, additional antihypertensive effects may occur. 
Care should be taken if labetalol is used concomitantly with calcium 
antagonists of the verapamil type. 
While taking beta-blockers, patients with a history of severe 
anaphylactic reaction to a variety of allergens may be more reactive to repeated 
challenge, either accidental, diagnostic, or therapeutic. Such patients may be 
unresponsive to the usual doses of epinephrine used to treat allergic reaction 
Contraindications 
Labetalol  injection is contraindicated in bronchial asthma, overt cardiac 
failure, greater-than-first-degree heart block, cardiogenic shock, severe 
bradycardia, other conditions associated with severe and prolonged 
hypotension, and in patients with a history of hypersensitivity to any 
component of the product 
Labetalol should not be used in patients with a history of obstructive 
airway disease, including asthma. 
Side effects 
Most adverse effects have been mild and transient. Symptomatic 
postural hypotension (incidence, 58%) is likely to occur if patients are tilted or 
allowed to assume the upright position within 3 hours of receiving labetalol . 
The incidence of adverse reactions depends upon the dose of labetalol. 
The largest experience is with oral labetalol. 
Cardiovascular: Hypotension, and rarely, syncope, bradycardia, heart 
block. 
Liver and Biliary System: Hepatic necrosis, hepatitis, cholestatic 
jaundice, elevated liver function tests. 
Hypersensitivity: Rare reports of hypersensitivity (e.g., rash, urticaria, 
pruritus, angioedema, dyspnea) and anaphylactoid reactions. 
Overdosage with labetalol causes excessive hypotension that is posture 
sensitive and, sometimes, excessive bradycardia. Patients should be placed 
supine and their legs raised if necessary to improve the blood supply to the 
brain. If overdosage with labetalol follows oral ingestion, gastric lavage or 
pharmacologically induced emesis (using syrup of ipecac) may be useful for 
removal of the drug shortly after ingestion. The following additional measures 
should be employed if necessary: 
Excessive bradycardia — administer atropine or epinephrine. 
Cardiac failure — administer a digitalis glycoside and a diuretic. 
Dopamine or dobutamine may also be useful. 
Hypotension — administer vasopressors, e.g., norepinephrine. There is 
pharmacologic evidence that norepinephrine may be the drug of choice. 
Bronchospasm —administer epinephrine and/or an aerosolized beta-
agonist.  
Seizures—administer diazepam. 
In severe beta-blocker overdose resulting in hypotension and/or 
bradycardia, glucagon has been shown to be effective when administered in 
large doses (5 to 10 mg rapidly over 30 seconds, followed by continuous 
infusion of 5 mg per hour that can be reduced as the patient improves). 
Neither hemodialysis nor peritoneal dialysis removes a significant 
amount of labetalol from the general circulation (<1%). 
Cautions 
If the patient has laboratory evidence of liver injury or jaundice, 
labetalol should be stopped and not restarted. 
The necessity or desirability of withdrawing beta-blocking therapy 
before major surgery is controversial. Protracted severe hypotension and 
difficulty in restarting or maintaining a heartbeat have been reported with beta-
blockers. The effect of labetalol’s alpha-adrenergic activity has not been 
evaluated in this setting. 
Caution must be observed when reducing severely elevated blood 
pressure. A number of adverse reactions, including cerebral infarction, optic 
nerve infarction, angina, and ischemic changes in the electrocardiogram, have 
been reported with other agents when severely elevated blood pressure was 
reduced over time courses of several hours to as long as 1 or 2 days. The 
desired blood pressure lowering should therefore be achieved over as long a 
period of time as is compatible with the patient’s status. 
Symptomatic postural hypotension (incidence, 58%) is likely to occur if 
patients are tilted or allowed to assume the upright position within 3 hours of 
receiving labetalol injection. Therefore, the patient’s ability to tolerate an 
upright position should be established before permitting any ambulation. 
Hypotension, bradycardia, hypoglycemia, and respiratory depression 
have been reported in infants of mothers who were treated with labetalol for 
hypertension during pregnancy. 
Small amounts of labetalol (approximately 0.004% of the maternal dose) 
are excreted in human milk. Caution should be exercised when labetalol is 
administered to a nursing woman. 
METHODOLOGY 
Study design; 
Prospective randomized comparative placebo controlled double blinded 
study 
Materials and Methods: 
Study population: 
90 ASA I and II patients aged15– 60 years undergoing elective ENT 
surgeries (mastoidectomy, FESS, stapedectomy and myringoplasty) under 
general anesthesia were chosen for the study. 
Exclusion criteria:  
Difficult airway 
Hypertension 
Diabetes mellitus 
Ischaemic heart disease  
Renal disease 
Cerebrovascular disease 
Patients on beta blockers, alpha blockers. 
Bronchial asthma 
Allergy to study drug 
Methodolgy: 
After obtaining ethical committee approval, the study population was 
chosen. All the patients were assessed preoperatively with history, clinical 
examination, and required investigations 
Informed written consent obtained from the patient.The surgeon was 
informed about the study. 
The patients were randomly allocated into three groups. 
Group D( 30 no) received Dexmedetomidine 1 µg/kg in 10ml normal 
saline i.v. over 10 min, 5min before induction of anaesthesia 
Group L (n:30) received Labetalol 0.5mg/kgin 10ml normal saline i.v. 
over 10min, 5min before induction of anaesthesia 
Group P (n:30)  received10ml normal saline i.v. over 10min, 5min 
before induction of anaesthesia 
 All patients were premedicated with Inj. Midazolam 2mg and Inj. 
Glycopyrrolate 0.2mg I.m. 45 min prior to surgery. Heart rate , systolic and 
diastolic blood pressure and oxygen saturation were recorded as base line 
value. 
All patients were monitored with ECG, pulse oximetry continuously and 
NIBP at 5 min intervals. Patients received study drug 5 min prior to induction 
according to the group. 
All patients were preoxygenated with 100% oxygen. Patients were 
induced with inj. Thiopentone 5mg/kg, Inj. Fentanyl 2µg/kg followed by 
Vecuronium 0.08mg.kg. Entotracheal intubation was done 2min after 
vecuronium. Anaesthesia was maintained with Isoflurane in oxygen and 
Nitrous oxide(33%and66%respectively). 
Parameters for analysis:  
SBP, DBP, MAP, HR and SpO2 were monitored 1 minute after infusion 
of study drug, 1minute after induction and 1,3,5,10 and15 minutes after 
intubation. 
During intubation, laryngoscopy duration and Cormack lehane score 
were noted. 
Any incidence of hypotension or bradycardia was recorded.Hypotension 
is defined as decrease in MAP 30% or more from baselineand treated with 
inj.ephedrine6mg.. Bradycardia is defined as HR<50/min and treated with 
inj.atropine0.6mg. 
 Results were tabulated and analysed 
RESULTS 
The study was done 1n 90 patients belonging to ASA class I and II 
undergoing elective surgeries under general anesthesia. The patients were 
categerised into 3 groups. 
Group D  Dexmeditomidine 
Group L  Labetalol 
Group P  Placebo 
Statistical analysis 
We used Chi-Square test, ANOVA and Post-Hoc test as appropriate. 
p<0,05 was considered statistically significant. The results were presented as 
means and SD. 
TABLE - 1  
DEMOGRAPHIC CHARACTERISTICS BETWEEN GROUPS 
Parameters Group D Group L Group P P value 
Mean age in 
years±SD 31.17± 11.8 34.5± 15 32.9 ±11.7 0.606 
Mean wt in 
kgs± SD 58.2± 9.8 58.1 ±9.2 56.8± 9.3 0.828 
SD- Standard deviation                       P>0.05-not significant 
TABLE - 2 
 Male Female 
Group D 19 11 
Group L 16 14 
Group P 11 19 
 
The groups were matched for demographic data, and there was no 
statistically significant difference found between the groups in age, sex and 
weight. 
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TABLE - 3 
BASE LINE PARAMETERS 
 
 Group D Group L Group P P Value 
SBP ±SD 119.3±8.8 121.5± 11 121.7 ±8.9 0.564 
DBP ±SD 78.8 ±6.65 81.2 ±6.7 80.4 ±5.4 0.339 
MAP ±SD 92.17 ±6.3 94.5 ±7.3 93.9 ±6.6 0.380 
HR±SD 85.13± 8.96 88.±10 81.8± 11 0.064 
SPO2±SD 99± 0.6 99 ±0.5 99± 0.6 0.916 
 
SD- Standard deviation               ‘P’Value >0.05 
 Baseline parameters are comparable between groups. There is no 
statistically significant difference between the groups. 
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 After administration of the study drug blood pressure, heart rate and 
saturation were recorded 1 minute following the injection of the drug, 1 min 
after induction,1 min, 3min, 5 min,10 min  and 15 min after laryngoscopy and 
intubation. 
TABLE – 4 
HEART RATE, SYSTOLIC BLOOD PRESSURE, DIASTOLIC BLOOD 
PRESSURE AND MEAN ARTERIAL PRESSURE AFTER DRUG INJECTION 
After drug 
injection Group D Group L Group p ‘ P’ Significance 
Heart rate 65.87±5.3 76.7±8.9 79.8±8.62 0.001 Significant 
Systolic B.P 118.07±9.5 113±8.3 119.8±8 0.709 Not significant 
DiastolicB.P 76.7±7.7 76.7±6 79.3±4.7 0.196 Not significant 
MAP 90.4±7.4 88.53±6.7 92.5±5.3 0.063 Not significant 
SPO2 98.7±0.7 99±0.5 99±0.5 0.101 Not significant 
 
FIGURE -  4 
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Table 4 shows the mean heart rate, mean systolic and mean diastolic 
blood pressure after injection. There is statistically significant difference in 
mean heart rate of patients across 3 groups (p< 0.01). The mean heart rate of 
group D is lower than that of both the  group L and P.  
There is no statistical difference in the mean systolic diastolic blood 
pressure and SPO2 among 3 groups. 
TABLE – 5 
DEVIATION OF HEART RATE FROM BASELINE 
 
Heart Rate Group D Group L Group P ‘P’ 
After drug 65.9 ±5.3 76.7± 9 80± 8.6 0.001 
After induction 73.3  ±4.13 83.5± 7.25 86.7 ±8.2 0.001 
After intubation 
1min 
76.4±5.6 95.2±10.6 114±12.97 0.001 
3 min 74.4±5.6 91±10.64 108±11 0.001 
5 min 72.5±5.77 86.57±8.9 100.7±9.69 0.001 
10 min 71.1±4.84 83.0±7.3 91.9±9.2 0.001 
15 min 70.83±4.1 81.3±7.2 87.47±7.7 0.001 
SD standard deviation         ‘P’<0.05-Significant 
Heart rate decreased after injection of the drug in dexmeditomidine 
group and labetalol group compared to placebo. The fall in heart rate  was more 
in group D than in group L. Heart rate increase after intubation is more in 
Placebo group than Group D or Group L.  
TABLE – 6 
COMPARISON BETWEEN GROUP D AND GROUP L 
Heart Rate 
Mean±Sd Group  D Group  L ‘P’ 
After drug 65.9 ±5.3 76.7± 9 0.001 
After induction 73.3  ±4.13 83.5± 7.25 0.001 
After intubation 
1min 
76.4±5.6 95.2±10.6 0.001 
3 min 74.4±5.6 91±10.64 0.001 
5 min 72.5±5.77 86.57±8.9 0.001 
10 min 71.1±4.84 83.0±7.3 0.001 
15 min 70.83±4.1 81.3±7.2 0.001 
 SD- Standard deviation         ‘P’<0.05-Significant 
 Heart rate response to laryngoscopy and intubation was effectivevely 
suppressed in dexmed group (GroupD) compared to labetalol group(Group L) 
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TABLE – 7 
COMPARISON  OF SYSTOLIC ARTERIAL PRESSURE RESPONSE 
Blood Pressure 
mean±SD Group D Group L Group P ‘P’ 
Baseline 119.3± 8.8 121.5 ±11 121.7± 8.9 0.564 
After Drug 118±9.5 113±8.3 119±8 0.090 
After Induction 112.4±8.5 108.9±8.3 111.3±9 0.288 
After Intubation 
1min 118.9±7.4 131.1±9.2 152.67±9.6 0.001 
3 Min 116.9±7.7 127.67±8.5 146±8.6 0.001 
5 Min 114.5± 7.8 124.9 ±8.1 139.7± 6.8 0.001 
10 Min 111.9 ±7.7 121.9 ±7.5 133.2± 6.7 0.001 
15 Min 111.8 ±6.8 120.23 ±7.3 127 ±6.1 0.001 
SD- Standard deviation       ‘P’<0.05-Significant 
FIGURE - 7 
TABLE – 8 
COMPARISON  OF DIASTOLIC ARTERIAL PRESSURE RESPONSE 
Blood pressure 
Mean±SD Group D Group L Group P ‘P’ 
Baseline 78.8±6.6 81.2 ±6.7 80.37±5.4 0.339 
After drug 76.73±7.7 76.7±6.3 79.33±4.9 0.196 
After induction 73.2±6.9 73.67±6.4 73.77±5.2 0.932 
After intubation 
1min 79.8±5.5 88±5.8 106.97±8.4 0.001 
3 min 76.73±4.7 86.57±6.2 101.73±6.8 0.001 
5 min 74.9 ±4.2 84.2± 5.9 96.3± 6.7 0.001 
10 min 73.73 ±3.4 80.8± 4.5 90.43± 6.4 0.001 
15 min 73.27± 3.4 79.8 ±4.8 83.87± 5.8 0.001 
SD- Standard deviation       ‘P’<0.05-Significant 
FIGURE - 8 
TABLE – 9 
COMPARISON  OF MEAN ARTERIAL PRESSURE RESPONSE 
Blood pressure 
Mean±SD Group D Group L Group P ‘P’ 
Baseline 92.17± 6.3 94.4 ±7.3 94± 6.3 0.380 
After drug 90.43±7.4 88.5±6.7 92.57±5.3 0.063 
After induction 86.47±6.7 85.1±6.6 73.77±5.2 0.701 
After intubation 
1min 92.87 ±5.5 102.7± 6.6 122.5 ±7.7 0.001 
3 min 90 ±4.8 100 ±6.6 116.37± 7.2 0.001 
5 min 88.1± 4.6 97.6± 6.3 110.3 ±6.5 0.001 
10 min 86.73 ±3.9 94.4 ±5.2 104.8 6.4 0.001 
15 min 86.13 ±3.8 93.2± 5.5 97.9 5.2 0.001 
SD- Standard deviation       ‘P’<0.05-Significant 
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TABLE – 10 
COMPARISON MAP GROUP DAND GROUP L 
Heart rate 
Mean±sd GROUP D GROUP L ‘P’Value 
Baseline 92.17± 6.3 94.4 ±7.3 0.379 
After drug 90.43±7.4 88.5±6.7 0.501 
After induction 86.47±6.7 85.1±6.6 0.686 
After intubation 
1min 
92.87 ±5.5 102.7± 6.6 0.001 
3 min 90 ±4.8 100 ±6.6 0.001 
5 min 88.1± 4.6 97.6± 6.3 0.001 
10 min 86.73 ±3.9 94.4 ±5.2 0.001 
15 min 86.13 ±3.8 93.2± 5.5 0.001 
SD- Standard deviation       ‘P’<0.05-Significant 
 SAP, DAP and MAP after injection of drug and after induction were 
comparable between the groups. There is no statistically significant 
difference(‘p’>0.05).  
 After laryngoscopy and intubation SAP,DAP and MAP increased at 
1min, 3min, 5min.10min and 15 min in group P compared to group D and 
group L (‘P’<0.05). 
In group D the pressures after intubation at 1min,3min, 5min, 10min and 
15 min intervals were less than group L. 
 Airway scoring;  MMS and CLG  were comparable between the groups 
TABLE – 11 
MODIFIED MALLAMPATTI CLASSIFICATION 
 MPC I MPC II 
GroupD 24 6 
Group L 24 6 
Group P 26 4 
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TABLE – 12 
CORMACK-LEHNE SCORING 
 
 CLG I CLG II a 
Group D 22 8 
Group L 25 5 
Group P 20 9 
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TABLE  - 13 
INCIDENCE OF COMPLICATIONS 
 Group D Group L Group P 
Hypotension Nil Nil Nil 
Bradycardia Nil Nil Nil 
DISCUSSION 
Larngoscopy and endotracheal intubation frequently induce a 
cardiovascular stress response characterized by hypertension and tachycardia. 
This sympathoadrenal stress response to laryngoscopy results in an increase in 
myocardial O2 demand leading to ischemia and acute heart failure in 
susceptible individuals. 
In view of the frequent occurrence of hypertension and tachycardia 
during laryngoscopy even in normotensive individuals, it is perhaps rather 
surprising that complications have not been met very often. One reason for this 
may be the transient nature of hypertension which usually lasts less than 10 
minutes. It is possible however that some of the complications that occur 
during intubation or even later in the course of anaesthesia may be precipitated 
by an episode of hypertension and tachycardia, following endotracheal 
intubation. ELLIOF (1980) observed left ventricular wall dysfunction 
following endotracheal intubation. 
This reflex sympathetic response may be diminished or modified 
locally, centrally and peripherally and attempts have been made to accomplish 
this using all these approaches with varying success. 
In an attempt to blunt these potentially adverse haemodynamic 
responses, different techniques and agents were used by many with varying 
success. 
  
 Sympathetic  system activation plays main role for the occurrence of 
transient but significant tachycardia and hypertension during intubation. Since 
any drug that antagonizes the  Sympathetic  system activation will attenuate 
these effects.  
STEINHAN and GASKIN (1963) used intravenous lignocaine, JAMES 
et al (1981) used lignocaine intratracheal spray, MASSON AND 
ECKANGOFF (1971) and DENLINGER J.K. (1974) and STOELTING (1978) 
used a combination of viscous lignocaine and topical intratracheal lignocaine 
and in 1979 LEAKO used a bolus of Sodium nitroprusside. 
J.CURRAN et al (1980) tried droperidol, A.J.COLE and C.JORDAN 
(1980) and RICHARD et al (1981) studied the effect of β blockers using 
metaprolol and propranolol respectively. LUNN (1979) BENNET and 
STANLEY (1980) and DONAL E.MARTIN (1982) studied the effect of 
fentanyl in attenuating the intubation stress response. 
SARVESH P. SINGH, ABDUL QUADIR compared the efficacy of 
esmolol and labetalol, in low doses, for attenuation of sympathomimetic 
response to laryngoscopy and intubation 
Inhalation agents when used required deep levels and may delay 
recovery after short surgeries and can cause cardio vascular depression 
Use of Vasodilators like Sodium nitroprusside results in reflex 
tachycardia, lability in blood pressure, cerebral vasodilation with elevation of 
intracranial pressure and pulmonary venous admixture  Opiod analgesics will 
attenuate the hemodynamics at the expense of respiratory depression. 
The α2 receptors are involved in regulating the autonomic and 
cardiovascular systems. α2 receptors are located on blood vessels, where they 
mediate vasoconstriction, and on sympathetic terminals where they inhibit 
norepinephrine release. α2 receptors are also located within the central nervous 
system and their activation leads to sedation, a reduction of tonic levels of 
sympathetic outflow and an augmentation of cardiac-vagal activity. This can 
result in a decrease in heart rate and cardiac output. 
The use of α2 agonists in the perioperative period has been associated 
with reduced anesthetic requirements and attenuated heart rate and blood 
pressure responses to stressfull events. In addition,α2 receptors within the spinal 
cord modulate pain pathways, thereby providing some degree of analgesia. 
Dexmedetomidine compared to Clonidine is a much more selective 
alpha2-adrenoceptor agonist, which might permit its application in relatively 
high doses for sedation and analgesia without the unwanted vascular effects 
from activation of alpha1-receptors. In addition, Dexmedetomidine is shorter-
acting drug than clonidine and has a reversal drug for its sedative effect, 
Atipamezole. These properties render Dexmedetomidine suitable for sedation 
and analgesia during the whole perioperative  period: as premedication, as an 
anesthetic adjunct for general and regional anesthesia, and as postoperative 
sedative and analgesic.  
It was observed that dexmedetomidine used in premedication supresses 
the sympathetic activation which is due to the endotracheal intubation. 
Dexmeditomidine reduces the opioid requirement  resulted in faster recovery 
It was observed that dexmedetomidine used in premedication supresses 
the sympathetic activation which is due to the endotracheal intubation. Güler et 
al. found that the increase in blood pressure and heart rate during the extubation 
is decreased and the quality of extubation is increased by dexmedetomidine 
Labetalol is an adrenergic receptor blocking agent with mild alpha1- and 
predominant beta-adrenergic receptor blocking actions (alpha:beta blockade 
ratio of 1:7 for iv and 1:3 for PO administration). The onset of action of i.v. 
labetalol is 5 min.  
Labetalol has the following advantages over other beta blockers 
1. Decrease SVR leading to decrease in BP is by alpha -1 blockade  
2. Vasodilation also produced by partial B2 agonist activity 
3. Reflex tachycardia due to peripheral vasodilation is attenuated by 
B blockade 
4. Cardiac output remains unchanged 
5. Presynaptic alpha-2 receptors are spared- hence release of 
Norepinephrine is intact, which inhibits further release of 
catecholamine  (Neg feedback mech)  
In our study we used Dexmeditomidine 1µ/kg and labetalol 0.5mg/kg 
and compared with placebo. Both the drugs produce peak effect after 5 
minutes. We had induced all the patients 5 minutes after preinjection.  
In some patients dexmeditomidine resulted in minimal increase in 
arterial pressure. This transient hypertension is due to α1mediated 
vasoconstriction. This transient hypertension is less than that seen with 
clonidine since dexmeditomidine has more selectivity over α2 receptors. 
Giving the loading dose over 20 minutes also minimizes the transient 
hypertension.34 
Bradycardia after dexmeditomidine was reported in some studies with 
the bolus injection. Scheinin et al reported that the use of2 agonist leads to 
bradycardia.35 
In our study dexmeditomidine over 10 min with continuous monitoring 
of heart rate, none of the patients developed bradycardia that required 
atropine.(table-3,13) 
Dexmeditomidine over 10 min with continuous monitoring of arterial 
oxygen saturation with pulse oxymeter showed no desaturation (spo2-<95%) in 
any patient. 
Ebert et al. didn’t observe any apnea, airway obstruction and hypoxemia 
with bolus doses of dexmedetomidine in their study and they reported that 
depression of respiration may be seen due to deep sedation36 
In another study in which the infusion of opioid and2 adrenergic 
agonists were compared, it was concluded that dexmedetomidine doesn’t cause 
significant respiratary depression and it decreases the risk of apnea . Hofer et al 
reported that dexmedetomidine seems to be a good choice in the critical 
patients in whom ventilation can be depressed with narcotics.37 
Labetalol in a dose of 0.5mg/kg had reduced the heart rate. But the 
reduction was modest compared to dexmeditomidine (table-3) the reduction in 
arterial pressure after labetalol was mild (table-9) that was statistically 
insignificant. 
Heart rate increase and arterial pressure reduction after induction was 
minimal in all 3 groups and there was no statistically significant difference 
between the groups. There was no significant hypotension on induction with 
dexmeditomidine or labetalol compared to placebo. (P>0.05 table-9) 
After intubation the blood pressure and heart rate were increased 
significantly in placebo group, while labetalol preinjection reduced the 
response significantly though there was a little rise in MAP and HR. (table-6,9) 
Dexmeditomidine preinjection effectively attenuated the hemodynamic 
response to intubation compared to labetalol. (table-6, 10) 
Sympathetic response to intubation lasted for 15 minutes. Arterial 
pressure and heart rate returned to baseline values in 15 minutes in placebo 
group. (table-6,9) 
In our study all the patients remained in supine position postoperatively. 
No postural hypotension related side effects were reported.(side effect seen 
with labetalol when the patient allowed to sit with in 3 hours after injection. 
Dexmeditomidine reduced the requirement of inhalational agents and 
opioids intraoperatively compared to placebo. 
With Labetalol the hemodynamics and anesthetic  requirements after30 
to 45 minutes were similar to placebo group. 
Extubation and recovery were comparable in all 3 groups  
Bolus dose of both Dexmeditomidine  and Labetalol were effective in 
attenuating the hemodynamic response to intubation, but the effect was 
complete and better with Dexmeditomidine 
SUMMARY 
This study was done to compare the efficacy of bolus injection of 
Dexmeditomidine   and Labetalol in attenuating the sympathoadrenal response 
accompanying laryngoscopy and endotracheal intubation in 90 patients divided 
into 3 groups. 
Group D - Dexmeditomidine 1µ/Kg 
Group L - Labetalol 0.5mg/Kg 
Group P –Placebo  
90 ASA I and II patients aged15– 60 years undergoing elective ENT 
surgeries (mastoidectomy, FESS, stapedectomy and myringoplasty) under 
general anesthesia were chosen for the study. After obtaining ethical committee 
approval, the study population was chosen. Informed written consent obtained 
from the patient. Heartrate, systolic and diastolic blood pressure and oxygen 
saturation were recorded as base line value. 
All patients were monitored with ECG, pulse oximetry continuously and 
NIBP at 5 min intervals. Patients received study drug  5 min prior to induction 
according to the group. SBP, DBP, MAP, HR and SpO2 were monitored 1 
minute after infusion of study drug, 1minute after induction and 1,3,5,10 and15 
minutes after intubation. 
 Results were tabulated and analysed. We used Chi-Square test, and 
ANOVA and Post-Hoc test as appropriate. p<0,05 was considered statistically 
significant. The results were presented as means and SD 
With patients matched for demographic data the results showed there 
was no significant difference in base line values between three groups. 
There was a reduction in the heart rate and mean arterial pressure 
response to intubation in both Dexmeditomidine and Labetalol groups 
compared with placebo (P<0.05), but when both the groups were compared 
there was statistically significant reduction of heart rate and arterial pressure 
response to intubation in Dexmeditomidine group. (P < 0.05). 
There were no significant hypotension or bradycardia in any of the 
groups. 
 CONCLUSION 
 We conclude that, Dexmeditomidine 1µ/Kg given slowly over 10 
minutes intravenously 5 minutes prior to induction, attenuates the 
cardiovascular responses to laryngoscopy and intubation in a better manner 
than Labetalol 0.5mg/Kg. 
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PROFORMA 
A COMPARATIVE STUDY OF DEXMEDETOMIDINE AND 
LABETALOL FOR ATTENUATION OF HAEMODYNAMIC STRESS 
RESPONSE TO LARYNGOSCOPY AND INTUBATION 
 
Name:                                       Age:               Sex:              Wt:     kg 
Date :                                        I.P. no:           ASA: 
Diagnosis:                                 surgery planned: 
History : 
Investigations : 
                           Hb%:                                                              Blood sugar:                                  
                           ECG                                                                            Urea:                                 
         Chest X ray                                                               Creatinine:                                 
O/E 
               Anaemia:                                        CVS;                           RS:  
                         PR:                                        BP: 
Pre-med     : Inj. Midazolam  2mgi.m 
Inj. Glycopyrrolate 0.2mg i.m.  45 min prior to surgery 
Group D      -  Dexmedetomidine 1 µg/kg in 10ml normal saline i.v. over 10 
min  5min before induction of anaesthesia 
Group L     -  Labetalol 0.5mg/kgin 10ml normal saline i.v. over 10min, 5min 
before induction of anaesthesia 
Group P    -  10ml normal saline i.v. over 10min, 5min before induction of 
anaesthesia 
Induction  :Inj Fentanyl 2 mcg/kg, 
Inj.thiopentone 5mg/kg, 
Inj.veccuronium 0.08 mg/kg 
Airway       :    ETT 
Maintenance : O2 / N2O / Isoflurane 
Parameters Monitored: 
Laryngoscopy duration:            in seconds 
Cormack lehane grade:      I / II/ III/ IV 
Haemodynamic variables Time in min 
HR SBP DBP MAP SpO2 
Baseline      
1 min after study 
drug 
     
1min after induction      
1 min after 
intubation 
     
3min      
5min      
10min      
15min      
Side effects : Hypo tension /  bradycardia / bronchospasm 
Name
DEXMED GROUP SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2
1 Babu 28/M 68 124 72 89 84 99 124 78 93 66 99 106 61 76 72 99 121 79 93 82 100
2 Nagaraj 45/M 71 134 82 99 78 98 119 74 89 65 98 108 67 79 68 100 131 79 96 72 100
3 Sarathkumar 18/M 65 126 86 99 75 99 119 69 86 61 99 110 61 87 71 100 128 81 97 73 100
4 Saraswathy 32/F 52 118 78 91 90 100 110 68 82 67 99 105 72 83 78 99 117 78 91 84 100
5 Premkumar 22/M 55 110 69 83 89 99 102 60 74 69 98 95 56 69 81 100 114 68 83 82 100
6 Zubi 15/F 50 130 71 91 93 99 122 72 89 79 99 121 73 88 82 100 128 78 95 88 100
7 Thasin 23/F 47 115 79 91 81 99 118 85 93 64 98 115 80 93 74 99 116 81 93 72 99
8 Wiilliams 39/M 70 108 77 87 107 99 107 78 88 76 98 105 77 87 75 100 110 79 89 79 100
9 Ponraj 21/M 56 111 83 92 84 98 102 71 81 66 97 105 75 85 74 100 115 85 95 82 100
10 Anand 32/M 58 115 78 91 84 98 121 88 99 64 98 114 78 90 72 100 120 79 92 78 100
11 Anandhi 16/F 45 108 76 87 99 99 109 79 89 70 98 101 71 81 77 99 109 81 91 77 100
12 Viji 27/F 65 116 88 98 89 99 121 88 99 65 99 115 86 95 72 100 120 89 99 76 100
13 Anand 24/M 59 121 82 95 83 99 122 81 94 65 98 123 81 97 77 100 123 83 99 80 100
14 Rajiv gandhi 27/M 75 117 74 88 88 98 117 76 90 61 98 114 72 86 71 99 121 76 91 71 100
15 Balan 22/M 69 118 73 88 98 98 119 73 87 71 98 118 72 87 74 99 118 80 93 74 99
16 Raja 26/M 59 125 88 100 87 99 109 73 85 74 99 107 66 79 81 100 108 74 85 78 100
17 Shanmugavalli 55/F 47 123 84 95 87 99 123 69 87 63 99 115 73 87 69 100 119 81 94 66 100
18 Raman 48/M 56 123 87 99 79 100 129 88 102 67 100 121 81 91 71 100 118 86 97 69 100
19 Suresh 20/M 61 119 76 90 67 100 126 75 92 58 99 117 73 88 68 99 119 73 88 69 99
20 Amudha 30/M 49 129 86 100 99 99 125 85 99 73 98 124 83 97 79 100 128 91 103 83 100
21 Valli 29/F 57 124 87 98 80 99 118 68 85 70 99 113 72 86 77 99 128 91 104 78 100
22 Pushpavalli 42/F 70 126 86 99 88 99 131 86 101 72 99 124 81 95 70 100 124 89 101 82 100
23 Srinivasan 26/M 60 108 73 85 78 98 108 77 87 62 99 103 72 82 69 99 106 75 85 78 100
24 Rani 26/F 39 105 71 82 89 100 96 73 81 61 100 93 70 78 75 100 105 71 82 84 100
25 Xavier 41/M 56 112 64 80 76 100 118 65 83 61 99 110 64 79 70 99 117 77 90 76 99
26 Gopi 30/M 59 132 84 100 88 99 136 89 105 64 99 123 79 94 71 100 128 79 95 78 100
27 Martin 40/M 73 128 86 100 69 100 134 88 103 58 99 125 79 94 71 100 124 81 95 69 100
28 Prabavalli 43/F 43 103 76 85 89 99 112 76 88 62 99 107 71 83 71 100 108 79 88 69 100
29 Veeramuthu 23/M 68 115 70 85 83 100 121 73 89 63 99 116 73 87 67 99 116 74 88 72 100
30 Indhiragandhi 65/F 44 136 79 98 73 99 124 77 93 59 100 119 77 91 71 99 129 77 94 71 100
S.NO   Age kg Baseline min after injection of study dru 1min after induction After intubation 1min
SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2
124 76 92 85 99 119 72 87 86 99 120 71 87 78 99 124 74 91 72 100 I I 17 I
134 79 97 78 100 131 81 98 76 100 129 72 91 74 100 123 73 90 69 99 I I 13 I
125 79 98 68 100 121 74 90 66 100 120 71 87 65 100 120 70 87 66 100 I I 15 I
117 75 89 88 100 115 75 88 86 100 110 74 86 80 100 114 72 85 79 100 I I 16 I
111 68 82 77 100 110 67 81 71 100 108 70 83 70 100 111 73 86 75 100 I I 12 II
125 75 92 79 100 118 73 88 78 99 115 73 86 73 100 113 69 84 73 100 II IIA 17 I
116 82 93 71 100 116 82 93 70 100 116 82 93 71 100 117 82 93 69 100 I I 15 I
107 77 87 77 100 105 77 86 79 100 105 76 86 78 100 104 75 85 79 100 I IIA 18 I
106 76 88 80 100 102 76 85 76 100 102 76 85 74 100 102 74 83 74 100 II I 14 I
119 75 90 70 100 120 74 89 72 100 110 70 89 70 100 105 74 84 70 99 I I 17 I
111 81 91 72 99 109 79 91 70 100 102 74 83 72 100 105 75 85 70 100 I IIA 16 I
121 85 96 70 100 115 70 85 74 100 114 74 87 71 100 112 71 84 73 100 I I 14 I
117 74 88 81 100 117 74 88 81 100 109 77 88 76 100 108 77 88 71 100 II IIA 17 II
118 71 87 71 100 114 70 85 70 100 112 70 84 71 100 112 71 85 70 100 II I 15 II
116 72 87 73 100 114 71 85 68 100 112 73 86 69 100 111 70 84 70 100 I IIA 16 I
103 70 81 76 100 104 71 82 73 99 103 72 83 70 99 102 71 83 71 100 I I 14 I
118 81 93 66 100 113 78 90 61 100 112 72 86 60 100 114 74 87 67 100 I IIA 15 I
115 83 94 68 100 115 79 91 65 100 114 79 91 68 100 114 78 90 67 100 I I 12 I
118 73 88 68 99 116 77 90 69 100 106 72 84 60 100 109 71 84 60 100 I I 14 I
129 89 101 78 100 127 85 99 69 100 119 81 96 70 100 119 80 95 70 100 I I 12 I
124 83 97 72 99 122 80 93 71 100 117 72 86 71 100 115 72 85 68 99 I I 13 I
116 73 87 82 100 114 73 87 81 99 114 73 87 81 100 119 73 88 80 100 II I 14 1
106 76 86 79 100 99 69 79 69 100 96 73 81 76 100 99 68 79 76 99 I I 12 I
106 74 85 78 100 99 70 80 73 100 96 66 76 70 99 98 67 77 70 100 I I 13 I
112 72 85 69 99 112 72 85 69 100 113 72 85 69 100 113 73 86 71 100 I I 17 I
121 78 92 76 100 121 76 91 71 100 122 74 90 69 100 118 76 89 70 100 I IIA 16 I
125 80 95 69 100 121 79 92 68 100 118 80 93 67 100 117 78 91 68 100 I I 13 I
108 75 86 70 100 106 75 85 69 100 107 74 85 69 100 107 74 85 68 100 I I 14 I
113 74 87 73 99 114 74 87 72 100 114 74 87 70 100 110 70 83 70 100 I I 14 I
127 76 93 68 99 126 75 92 72 100 123 75 91 70 100 119 73 88 69 100 II IIA 19 II
3min
CLG Duration of laryngoscopy ASA5 min 10 min 15 min MMS
Name
labetalol group SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP
1 Shanthi 48/F 54 126 84 97 94 99 126 82 97 89 99 114 70 85 92 100 138 90 106 98 100 136
2 Praveenkumar 15/M 47 116 76 89 98 99 110 70 83 79 99 109 73 85 88 100 132 89 104 90 100 129
3 Antony 15/M 51 109 77 90 99 98 100 70 80 77 99 96 73 81 83 100 129 85 100 99 99 123
4 Marikannan 27/M 67 115 74 88 78 99 112 79 83 82 100 104 72 83 82 100 134 89 104 90 100 124
5 Ruckmani 41/F 59 139 92 104 93 99 112 72 86 78 100 100 68 79 83 100 131 91 104 74 100 132
6 Sasikumar 22/M 70 136 90 105 93 100 132 88 103 82 99 132 88 103 87 99 131 93 106 99 100 131
7 Aadhilakshmi 40/F 55 114 84 94 104 99 109 82 91 96 100 97 69 78 98 100 103 74 84 103 100 104
8 Gangalakshmi 40/F 69 116 75 89 89 99 108 66 80 78 100 102 69 80 93 100 130 87 101 105 100 119
9 Nithya 15/F 43 115 76 89 110 99 111 73 85 102 99 108 70 83 104 99 118 78 91 103 100 113
10 Narasimma moorthy 46/M 78 120 80 93 82 99 112 76 88 76 100 110 70 83 84 100 138 92 107 101 100 132
11 Elango 18/M 62 114 87 96 91 99 110 78 89 78 100 107 79 87 89 100 131 89 103 99 100 129
12 Ramesh 15/M 59 114 81 92 94 98 112 80 91 78 100 108 74 85 84 100 134 89 104 102 100 131
13 Jeevitha 15/F 55 108 73 85 97 99 101 71 81 79 99 96 70 79 82 100 129 83 98 110 100 126
14 Perumal 46/M 65 131 88 102 88 98 117 78 89 70 100 117 86 96 82 100 137 96 110 88 100 132
15 Jeya 20/F 50 110 75 87 90 99 107 71 83 83 100 103 73 83 82 100 128 85 99 96 100 127
16 Chinnaraj 45/M 68 130 88 102 72 99 105 70 82 70 99 108 70 83 83 100 128 99 109 122 99 128
17 Jeyaraman 61/M 60 141 81 101 71 100 114 78 90 60 99 112 75 87 74 100 148 92 111 88 100 141
18 Parvathy 40/F 39 139 93 108 81 100 128 87 101 71 100 121 85 97 79 100 146 95 112 91 100 141
19 Selvi 20/F 38 108 78 88 97 99 100 71 81 72 100 94 72 79 82 100 134 88 113 102 100 124
20 Perumal 55/M 59 139 89 104 92 99 126 82 97 76 100 114 70 85 82 99 139 96 110 103 100 136
21 Raj 36/M 60 127 86 100 99 98 114 81 92 79 99 112 81 90 82 100 130 91 104 111 100 127
20 Irulammal 38/F 56 119 81 94 73 99 112 83 93 66 100 110 80 90 87 99 128 91 104 91 100 123
23 Muralidharan 41/M 61 129 83 98 89 99 125 84 98 74 99 117 80 92 84 100 132 89 103 93 100 131
24 Sathish 27/M 71 118 73 88 76 99 112 70 84 70 100 110 67 79 78 100 130 80 97 86 100 126
25 Kalyani 46/F 56 125 75 91 71 99 112 72 85 63 99 110 70 83 71 100 131 82 98 80 100 125
26 Mani 16/M 49 110 68 82 96 99 110 64 79 88 100 110 60 73 88 100 126 80 95 98 99 126
27 Mohudheen 46/M 57 140 93 109 74 100 124 85 98 71 99 120 84 96 72 100 151 95 112 79 100 149
28 Saradha bai 65/F 65 119 82 94 77 99 118 80 93 71 100 115 72 86 78 100 129 83 98 79 100 126
29 Mariammal 51/F 58 112 78 89 89 99 109 82 91 76 100 112 70 82 82 100 121 86 98 87 100 120
30 Revathy 26/F 61 107 76 86 86 99 103 76 83 69 100 100 70 80 71 99 117 85 96 88 100 119
1min after injection of study drug 1min after induction After intubation 1min
S.NO   Age kg Baseline
Duration of laryngoscopy
DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 Sec
92 107 96 99 129 89 102 92 100 124 85 98 90 100 116 76 89 79 100 II I 14 I
87 101 86 100 128 87 101 87 100 125 84 98 84 100 119 79 93 86 99 I I 17 I
82 96 96 100 124 81 95 91 100 119 79 92 87 100 110 76 87 83 100 I I 18 I
88 100 84 100 120 85 97 80 100 122 87 99 78 100 115 81 92 78 100 I I 15 I
90 104 76 100 135 90 105 72 100 134 88 103 72 100 137 84 102 72 99 II IIA 19 I
93 106 94 100 132 93 106 91 100 123 83 96 86 100 124 84 97 87 99 I I 12 I
73 82 94 100 100 77 85 96 100 101 76 84 92 99 117 87 97 91 100 I I 8 I
77 91 91 100 115 74 88 90 100 115 74 88 90 100 109 74 86 93 100 I I 14 I
75 88 106 100 114 72 85 102 100 114 72 86 100 100 111 69 83 100 99 I I 9 I
89 103 100 100 130 89 102 94 100 124 78 93 91 100 121 84 96 79 100 II I 12 I
88 101 96 99 129 85 100 91 100 124 81 95 88 100 121 78 92 81 100 I I 14 I
85 101 96 100 127 84 98 92 100 125 80 95 82 100 121 74 83 80 100 I I 12 I
83 97 106 100 121 80 94 100 100 111 77 90 92 100 110 75 87 92 99 I I 21 I
95 107 85 100 134 95 106 75 99 123 78 93 78 100 112 77 89 75 100 II I 17 I
89 100 94 100 114 81 92 81 100 112 80 90 72 99 114 80 90 71 100 II I 12 I
99 109 121 100 133 90 104 107 100 127 88 101 94 100 121 87 97 90 99 I IIA 20 I
91 108 87 100 138 91 107 81 100 130 82 99 82 100 132 81 98 83 100 II IIA 21 II
92 108 88 100 129 90 103 82 100 131 88 102 80 100 130 88 102 76 99 I IIA 21 I
87 99 98 100 126 87 100 93 100 121 81 94 84 100 117 82 95 81 99 I I 13 I
92 107 94 100 129 92 104 90 100 131 82 99 74 100 127 84 98 70 100 i IIA 19 I
92 104 103 100 126 86 99 94 99 121 82 96 92 100 123 84 97 89 100 I I 14 I
84 97 81 100 119 80 93 80 100 119 78 88 80 100 119 79 89 80 100 I I 15 I
87 102 88 99 129 87 100 83 100 128 85 99 82 100 128 84 99 83 100 I I 16 I
83 97 83 100 123 80 93 78 100 121 78 92 78 100 120 77 91 78 100 I I 17 I
79 94 78 100 123 77 92 76 100 121 77 91 74 99 120 75 90 76 100 I I 17 I
82 97 101 100 123 77 92 91 100 120 76 91 84 100 118 76 90 84 100 I I 12 I
94 112 77 100 139 87 104 77 100 137 88 104 75 100 137 87 104 77 99 I I 15 I
81 97 73 100 125 82 96 75 100 127 83 97 77 100 123 82 95 75 100 I I 14 I
83 95 78 100 118 77 91 78 100 118 79 92 76 100 119 77 91 75 100 I I 17 I
85 96 85 100 117 81 93 78 99 110 75 87 77 99 116 73 97 74 100 I I 18 I
15 min
MMS CLG ASA
3min 5 min 10 min
           Name
NORMAL SALINE SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2
1 Ruckmani 45/F 51 132 82 98 88 99 130 80 96 82 99 110 73 83 86 99 159 101 120 112 99
2 Padmawathy 30/F 47 100 70 80 92 99 104 69 81 90 99 92 64 73 96 100 130 92 105 114 100
3 Rajeshwari 40/F 51 124 84 97 88 98 121 85 97 82 98 104 74 79 92 100 147 99 115 114 100
4 Shalini 28/F 44 116 74 89 72 99 114 77 89 74 99 109 71 82 82 100 171 108 129 102 100
5 Mariammal 23/F 56 129 82 98 100 99 126 80 95 97 99 118 75 89 102 100 169 118 131 138 100
6 Vadivel 55/M 68 110 70 83 64 100 107 72 84 67 100 94 62 73 74 100 151 100 117 96 100
7 Priya 16/F 49 130 78 95 87 99 128 78 94 85 99 124 75 92 92 100 150 101 118 118 100
8 Kowsalya 34/F 55 121 86 98 84 98 118 82 94 76 99 108 80 89 76 100 165 126 139 118 100
9 Jeyanthi 37/F 49 130 90 103 91 99 127 88 101 87 99 118 80 93 97 100 160 119 133 132 99
10 Srinivasan 22/M 67 135 85 102 74 100 131 82 98 72 99 116 75 88 85 100 162 110 126 108 100
11 Kousi begam 16/F 43 121 81 94 71 99 118 79 92 79 99 113 71 85 88 99 154 114 127 119 100
12 Santhosh 21/M 62 118 76 89 78 98 115 73 87 72 98 109 72 84 81 100 139 90 106 119 100
13 Annalakshmi 33/F 57 114 82 93 82 99 116 84 95 89 99 110 82 91 94 100 135 99 111 102 100
14 Sasikumar 22/F 65 114 74 87 67 99 112 72 85 65 98 107 67 80 75 100 149 109 123 101 100
15 Vijaya 44/F 49 141 84 103 88 99 131 83 99 88 99 125 78 99 91 100 155 96 116 104 100
16 Raju 26/M 71 129 86 100 75 99 127 84 98 77 99 124 80 95 85 100 149 107 121 131 100
17 Gunalan 43/M 67 121 84 98 61 98 120 85 97 67 100 114 82 93 81 100 154 110 125 98 100
18 Sathish kumar 18/M 75 107 72 82 110 100 106 72 83 101 100 96 70 79 108 100 139 96 121 134 100
19 Sathya 19/F 49 117 84 95 73 100 115 82 95 75 99 103 74 84 73 100 158 109 128 101 100
20 Kumar 30/M 59 124 82 96 79 100 120 82 95 75 99 117 80 92 87 100 157 109 125 129 99
21 Anjalai 48/F 48 131 84 100 67 99 127 82 91 71 98 121 76 91 82 99 161 112 128 92 100
22 Aadhilakshmi 40/F 51 127 74 92 72 99 125 72 89 77 99 117 65 82 83 100 151 109 123 112 100
23 Devi 33/F 63 125 81 95 88 99 121 79 93 74 99 114 72 82 79 99 156 110 125 99 100
24 Sarala 29/F 41 117 84 95 91 99 114 82 92 79 99 110 79 89 85 100 154 107 123 128 99
25 Usha 19//F 51 121 81 94 88 98 118 79 92 82 99 103 71 81 87 100 154 114 127 117 100
26 Fathima 29/F 58 117 74 85 86 100 115 76 89 77 99 107 69 82 87 100 147 109 122 121 100
27 Chinnakannu 52/M 59 120 84 96 87 100 131 85 100 85 100 120 74 89 88 100 160 118 132 135 100
28 Kannan 35/M 61 124 81 95 88 99 127 79 94 84 99 124 74 91 90 100 144 106 119 112 100
29 Parthasarathy 57/M 71 127 88 101 71 99 125 83 97 76 99 114 76 89 79 100 159 113 128 99 100
30 Loganathan 43/M 68 109 74 85 92 99 106 74 85 90 99 99 72 81 96 100 141 98 112 114 100
S.NO   Agex/se Wt(kg) Baseline 1min after injection of study drug 1min after induction After intubation 1min
MMS CLG Duration of laryngoscopy ASA
SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 SBP DBP MAP PR SPO2 I I 11 I
142 100 113 104 100 133 94 106 93 100 130 90 103 90 100 127 89 100 90 100 I IIA 13 I
124 86 99 106 100 120 80 93 100 100 116 74 87 92 100 114 72 86 90 100 II IIA 15 I
141 96 111 113 99 134 90 105 110 100 134 84 100 90 100 132 84 98 89 100 I I 13 I
164 108 127 99 100 144 94 110 96 99 129 90 114 93 99 118 75 89 84 100 III IIA 13 I
158 107 124 130 100 150 101 117 120 100 134 94 107 113 100 124 87 99 106 100 I I 16 I
139 90 103 92 100 139 90 100 84 100 121 79 93 76 100 118 70 86 70 100 I I 14 I
143 94 110 114 99 142 93 109 112 100 135 91 106 99 100 131 82 98 91 100 I I 13 I
152 104 120 109 100 146 101 116 103 100 137 96 110 90 100 124 87 99 82 100 I I 14 I
144 99 113 120 100 141 96 109 114 99 137 95 107 103 100 132 87 99 92 100 I I 13 I
157 108 124 96 100 142 95 111 86 100 139 91 107 72 100 136 88 104 71 100 I I 14 I
146 107 120 117 100 140 100 113 105 99 134 94 107 99 100 127 84 98 91 100 I I 15 I
136 92 107 112 100 132 87 102 104 99 125 89 98 92 100 121 79 93 85 100 I I 14 I
131 91 104 115 100 127 86 100 112 100 121 79 93 99 100 119 81 94 92 100 I IIA 15 I
147 106 120 98 100 142 99 113 91 99 131 90 104 87 100 130 82 98 86 100 I I 12 I
151 92 112 100 100 144 87 106 100 99 145 84 104 97 100 140 82 101 90 100 II IIA 21 I
142 104 117 123 100 139 101 114 112 100 129 90 103 98 100 127 90 102 90 100 I I 16 I
151 107 122 90 100 144 106 119 86 99 135 94 108 73 100 131 89 101 74 100 I I 14 I
136 94 108 126 100 132 89 103 110 100 129 85 100 95 100 121 74 90 96 100 I IIA 17 I
152 106 121 99 100 149 105 118 96 100 142 97 112 87 100 130 89 102 81 100 I I 19 I
154 107 123 117 100 149 100 116 100 100 142 97 112 91 100 134 92 106 78 100 I IIA 19 I
154 110 125 94 100 147 106 120 89 99 142 98 113 82 100 130 90 103 83 100 I IIA 17 I
147 106 119 103 100 142 101 114 93 100 137 94 108 88 100 131 86 101 88 100 I I 16 I
152 108 122 95 100 144 104 117 93 100 134 94 107 89 100 128 86 100 88 100 I I 17 I
150 102 118 109 99 142 91 108 101 99 136 84 101 92 100 124 82 96 87 100 I I 17 I
146 107 120 104 100 140 100 113 96 100 134 94 107 94 100 127 84 98 92 99 I I 15 I
142 106 118 112 100 134 96 108 98 99 129 90 103 88 99 121 86 97 89 100 I I 17 I
154 108 123 124 100 142 100 114 110 100 140 94 109 99 100 136 89 105 97 100 I I 19 II
142 102 115 110 100 134 100 111 111 99 131 99 110 106 99 127 86 100 96 100 I I 17 I
149 108 122 93 100 144 105 118 89 100 139 99 112 82 100 130 90 103 82 100 II I 14 I
134 97 111 116 100 134 92 106 108 100 129 84 99 102 100 121 74 91 94 100 I IIA 19 I
5 min 10 min 15 min3min
